F2 and Cirrhosis: Univariate Cox regression analysis identified cirrhosis, ALT levels of ≥5 × ULN, higher prothrombin time (PT), and an HBsAg decline of ≥75% at Month 3 of treatment in HBeAg-positive patients and at Month 12 of treatment in HBeAg-negative patients as the significantly associated factors (Table 2).